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	 	 	 Abstract
26 consecutive patients (37 hips) with avascular necrosis (AVN) of  the 
femoral head treated surgically at our institution from 1999 to 2008 
were reviewed . The aims of  the study were to evaluate the risk factors 
associated with AVN in HIV positive and HIV negative individuals, and 
assess early response to total hip replacement (THR) surgery in HIV 
positive and negative patients. There were 15 male and 11 female patients 
in total. The mean age for all patients was 47.1± 8.0 years (range, 33 to 66 
years). 12  patients were HIV positive, 11 patients were HIV negative and 
3 patients had unknown HIV status. Excessive alcohol intake was the most 
common risk factor for developing AVN .15 patients (58%) had more 
than one risk factor for AVN and only 2/12 (17%) HIV positive patients 
had no other risk factor apart from HIV infection. There were no early 
postoperative complications in 34 arthroplasties in both HIV positive and 
negative patients. The aetiology of  AVN seems often to be multifactorial, 
even in the presence of  HIV infection. Early response to arthroplasty 
surgery in AVN of  the femoral head is equally good irrespective of  the 
HIV serostatus of  the patients.
   
Introduction
Avascular necrosis (AVN) of  the femoral head, also known 
as osteonecrosis, is a condition in which there is cell death 
of  various bone components including haematopoietic fat 
marrow and mineralised tissue. The estimated incidence 
of  AVN in the general population is 0.135%1,2. There are 
several aetiological factors that may result in AVN. Risk 
factors for osteonecrosis can be divided into traumatic 
and non traumatic. Traumatic causes include fractures 
and dislocations. Non-traumatic causes include: systemic 
steroids, alcohol abuse, hyperlipidemia, hypercoagulability, 
sickle cell disease, smoking, Gaucher’s disease, collagen 
vascular disease, deep sea diving, pregnancy, pancreatitis and 
irradiation. In 8-20% of  AVN cases, no association with the 
known risk factors has been noted1. 
AVN of  the femoral head is an emerging condition in HIV 
infected patients1-5,7,8,10,11,13. Whether osteonecrosis is an 
HIV-related complication, an adverse effect of  antiretroviral 
(ARVs) therapy or is caused by another HIV associated 
condition remains unclear5. The reported estimated 
incidence of  AVN in HIV patients ranges from 0.45 to 
1.33%5-9 which is greater than in the general population. 
Some authors have attributed the increasing incidence to 
hypertriglyceridaemia, which is frequently seen in HIV 
positive patients. Hypertriglyceridaemia secondary to use of  
protease inhibitors has also been reported1,7,8. 
The HIV prevalence rate among adults in Malawi is 11.9%14. 
There have been some reports in the infectious diseases and 
HIV/AIDS literature about the development of  AVN in HIV 
positive patients. However, we found only 2 reports relating 
to HIV and AVN in the orthopaedic literature13,16, one of  
which was pertaining to outcome of  surgical intervention, 
but not indexed on a Medline search.  
Avascular necrosis of  the femoral head, traumatic and non-
traumatic, is the leading cause of  total hip joint replacement 
(THR) in Malawi, accounting for 53% of  the cases17. It is 
not clear what proportion of  non-traumatic AVN patients 
are HIV positive.  No study has been done to assess the risk 
factor profile of  AVN patients in Malawi and  the association 
between HIV infection and AVN. In addition, it is not 
known whether early response to hip replacement surgery 
is different between HIV positive  and negative patients. 
Thus this study set out to assess for other risk factors of  
AVN  in HIV positive patients and see if  the association may 
be multifactorial; explore the alleged association  of   AVN 
and ARVs;  and assess the early response to hip replacement 
surgery. 
Methods	and	Materials
All patients with non-traumatic avascular necrosis of  the 
femoral head who underwent a total hip replacement surgery 
between 1999 to 2008 were identified from the National 
joint registry database17. The study duration was chosen to 
assess the first 10 years of  the joint registry. THR which 
involves prosthetic replacement of  both the acetabulum and 
the femoral head, is the definitive treatment for patients with 
advanced AVN. In addition 2 patients who had avascular 
necrosis of  the femoral head and were treated at our 
institution by core decompression in the same time-period 
were also included in the study.Core decompression surgery 
is done in patients with early AVN (pre-collapse stage), during 
which the necrotic femoral head is drilled to decompress the 
increased intraosseus pressure in the femoral head and neck 
of  patients with AVN thereby improving blood supply.  One 
patient had total hip replacement (THR) in one hip, and 
core decompression in the other . Thus all patients receiving 
surgical treatment for AVN were included. This maximised 
numbers for risk factor evaluation, but assessment of  
outcome of  surgery was restricted to total hip replacement 
patients to keep the group homogenous.
The diagnosis of  AVN was made clinically and using 
plain radiographs because plain radiography was the only 
imaging technique available in Malawi during the study 
period. Core decompression was done if  there was no 
collapse or fragmentation of  the femoral head, whereas 
THR  was done if  there was fragmentation, collapse or 
secondary degenerative changes of  the hip joint and the 
clinical symptoms warranted THR. All the patients in the 
study had no symptoms and signs suggestive of  sickle cell 
disease. The National joint registry records all cases of  joint 
replacement in Malawi. It had a total of  67 patients (81 total 
hip replacements) from 1999 to 2008. Approval from the 
local ethics committee was obtained and individual informed 
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consent was obtained from each patient in the study group.
The study group provided data on all AVN patients coming 
to surgery, and allowed comparison between HIV positive 
and negative patients in terms of  AVN risk- factor profile and 
outcome after surgery. The group consisted of  26 patients, 
who underwent a total of  34 primary total hip arthroplasties 
and 3 core decompressions.  
Data on patient characteristics, risk factors for avascular 
necrosis, HIV status, ARVs, and follow up were extracted 
from the National joint registry database using a proforma. 
The medical records and the x-rays of  these patients were 
also reviewed.  Risk factor profile data that was not available 
in the medical records and the database was obtained from 
the patients at the time of  this analysis, either through 
telephone or direct interview. Assessment of  early response 
to THR surgery was done by comparing pre-operative 
and post-operative Harris Hip score, a well known score 
in orthopaedics used to assess hip function and pain. In 
addition we reviewed the registry for documentation of  any 
major complications such as deep venous thrombosis, early 
sepsis and dislocations. 
Consent was obtained to collect blood samples to check 
non fasting cholesterol and triglyceride levels, as this is not 
routine in the registry. We assumed that abnormal levels of  
cholesterol and triglyceride in the blood are likely to remain 
elevated if  not treated and none of  the patients in the study 
were on special diets or cholesterol lowering drugs; thus all 
lipid profiles were taken at the time of  this analysis.
Patients were considered as having hypercholesterolemia 
if  the serum total cholesterol was > 200mg/dl and 
hypertriglyceridemia if  the serum triglyceride level was> 
200mg/dl. The reference levels were given by the laboratory 
that measured the blood samples.
Alcohol intake was considered a risk factor for males if  the 
weekly consumption was >37.5 units  within 2 years before 
the onset of  symptoms of  AVN [18]. No female admitted to 
taking alcohol.  Oral steroids were considered as a risk factor 
if  the patient had taken about 1800 mg prednisolone or an 
equivalent over 4 weeks19.
With regard to statistical analysis, all statistical analyses were 
done using SPSS 16.0 statistical program. Hypothesis testing 
was done using Fisher’s chi-squared test for categorical 
variables and Man-Whitney U test for continuous variables. 
Seroprevalence of  HIV in AVN patients was compared with 
seroprevalence in the general population using two sample 
test of  proportion.The level of  statistical significance was 
p<0.05 for all statistical analyses.
Results
Patient Characteristics 
Table I shows baseline characteristics of  the study patients. 
There were 15 males and 11 females. The mean age of  the 
patients in the study group was 47.1± 8.0 years (range, 33 
to 66 years). There were more obese patients (BMI>30) in 
the HIV seropositive group  than in the seronegative group, 
however the difference in the mean BMI was not statistically 
significant (p= 0.141). 
HIV Seroprevalence, Use of  ARVs, HIV stage and CD4 
count 
In our study 88.5% (23/26) of  the AVN patients were tested 
for HIV, and 46% of  them were HIV seropositive. Given 
that the background population seroprevalence is 11.9%14, 
the seroprevalence is 4 times higher among the AVN patients 
compared to the general population. This difference was 
statistically significant (p<0.001). 
Five patients had symptoms before and 7 patients had 
symptoms after starting antiretroviral drugs. Only 3 patients 
were taking protease inhibitors as part of  their regimen at 
the time of  first symptoms of  AVN. Only 2 patients whose 
symptoms developed after they had started taking ARVs had 
no other known risk factors. 
More than half  of  the HIV seropositive patients (7/12) had 
a diagnosis of  AVN when the clinical stage of  HIV/ AIDS 
was quite advanced (see figure 2). Data on CD4 counts at 
the time of  AVN diagnosis was available in 7 patients. Four 
patients had a CD4 count between 200- 499 cells/ul (normal 
is >1000cells/ul) at the time of  AVN diagnosis (Table 2). 
Table 1: Baseline Characteristics of Study Participants 












HIV seropositive 30.7 ± 5.6 (p= 0.141)
HIV seronegative 26.8 ± 5.9
Mean Pre op Harris Hip 
Score
HIV seropositive 24.3 ± 11.8 (p=0.495)
HIV seronegative 27.9 ± 8.8
Surgical intervention
THR (No. of hips)
HIV seropositive 15
HIV seronegative 16





Unknown HIV serostatus 1
Table 2: CD4 count at the time of AVN diagnosis (known in 7/12 
HIV patients 
CD4 count (cells/ ul) Number of patients
≥500 2
200 – 499 4
< 200 1
Table 3: HIV Serostatus and Anatomical distribution of AVN 
AVN sites     Negative Positive Unknown Total
1hip 4 (36) 3 (25) 1 8
2hip 7 (64) 8 (67) 2 17
Multifocal 0 1 (8) 0 1
Malawi Medical Journal; 25(2): 28-32 June 2013 Avascular necrosis 30
Risk Factors
The most common risk factor in the study group was 
excessive alcohol intake accounting for 12/26, 2 patients 
started having symptoms suggestive of  AVN while they 
were pregnant ( Figure I). More than half  of  the patients had 
more than one risk factor for AVN and only 2 patients out 
of  12 HIV positive patients had no other risk factors (Figure 
I). Figure I also shows the numbers of  patients in separate 
risk factor groups who were HIV positive. 
Figure 1: Risk factors of Avascular Necrosis
We managed to check cholesterol and triglyceride levels in 
9 HIV positive and 10 HIV negative patients. The mean 
cholesterol level in HIV seropositive and seronegative 
patients was 190.0 mg/dl ± 47.80 and 183.7mg/dl± 37.5 
respectively. The mean triglyceride levels in the HIV 
seropositive and seronegative patients were 144.0mg/dl 
± 71.3 and 129 mg/dl ± 81.4 mg/dl respectively. These 
differences were not statistically significant (p= 0.604). The 
serum total cholesterol levels were elevated in 4/9 HIV 
positive patients and 3/10 HIV negative patients. The serum 
triglyceride levels were elevated in 4/9 HIV positive patients 
and in 2/10 HIV negative patients. 
There was no statistically significant difference in the 
anatomical distribution of  AVN sites between the seropositive 
and seronegative groups (p= 0.4) (Table 1).  One patient in 
the seropositive group had multifocal disease involving both 
hips and both shoulders. 
Early response to surgery:
Only three patients had core decompression compared to 
23 patients who had 34 total hip replacement operations. 
For the arthroplasty patients, the mean pre operative Harris 
hip scores  were 24.3± 11.8 and 27.9± 8.8 in the HIV 
positive and negative groups respectively. This difference 
was not statistically significant (p= 0.495). The mean post 
operative Harris Hip Score at 6 months to one year in the 
HIV seropositive and seronegative groups were 82.9 ± 3.9 
and 84.9 ± 8.5 respectively. Again this difference was not 
statistically significant (p= 0.9). The median prosthetic 
duration in those patients who had a total joint replacement 
was 36 months (range 0 to 96 months). 
There were no major complications like deep venous 
thrombosis, early sepsis, dislocations or late sepsis. There 
were no patients lost to follow up. There was one death, 
in an HIV positive patient who died of  AIDS-related 
complications 8 years after arthroplasty. 
Discussion
Many have observed an association between HIV disease 
and AVN, but a causal link or indeed a discrete mechanism 
has not been defined. This study has shown an association 
between HIV disease and AVN of  the hip (p<0.001). 
However, we only found two articles  on this subject in the 
orthopaedic literature [13,16] where as they were several in 
infectious disease literature, thus it seems most orthopaedic 
surgeons are unaware of  the association between HIV and 
AVN. Many standard orthopaedic texts and web sites do not 
mention it, whilst mentioning some very rare risk factors20-22
The reported proportion of  idiopathic AVN among AVN 
patients ranges from 8- 20%. In our study 11.5% had no 
known risk factors for AVN. Fifteen (57.7%) had more 
than one risk factor for AVN and only 2 patients out of  12 
HIV positive patients had no other risk factors apart from 
HIV infection. This finding supports a concept that the 
aetiology of  AVN may frequently be multifactorial including 
in the presence of  HIV infection. The most common risk 
factor for the development of  AVN in our study group 
was excessive alcohol intake. Four out of  five patients who 
had used steroids were HIV positive. Steroids are used in 
the management of  a number of  HIV related conditions. 
The pathology of  steroid and alcohol induced AVN is not 
very clear but it has been suggested that they may cause 
fatty infiltration of  the bone marrow thereby compromising 
blood supply1,11,12. They may also promote fat embolism 
within the bone vasculature1,12. Our findings agree with what 
other studies have already found that certain risk factors are 
more prevalent in HIV positive patients1,2. 
The suggested aetiology of  AVN in HIV positive patients 
includes hypertriglyceridaemia and altered lipid metabolism. 
This would be consistent with a synergistic effect between 
alcohol or steroids and HIV seropositivity. In neither group 
were mean levels above the normal range, but there were a 
few patients in both groups whose lipid levels were above 
the normal range. This calls for another study with a larger 
sample size and controls from the normal population.  
Several authors have alluded to an association with ARVs and 
more specifically protease inhibitors 5, 7-10, 23,27. Only 3 patients 
out the 7 who had symptoms after they started taking ARVs 
were taking a protease inhibitor at the time of  AVN diagnosis 
in our study. We managed to check lipid levels for only one 
out of  these three patients, and the levels were normal. The 
suggested mechanism, by which protease inhibitors may be 
implicated in the aetiology of  AVN in HIV positive patients, 
is due to induction of  hyperlipidaemia [2,3,5-8, ]. Scribner et 
al found saquinavir to be associated with the development of  
AVN. However the findings in our study show   that protease 
inhibitors are not solely responsible for AVN. In fact, case 
reports of  AVN in HIV positive patients began to appear in 
the literature before the advent of  these drugs1, 2, 6, 7, 9, 10.
One of  the limitations of   our study was lack power because 
of  the relatively small sample size  and lack of  a control group, 
thereby making it difficult to make definite conclusions. 
There is therefore need for a case control study  in future 
to mitigate these limitations., However there are still some 
important findings that should be considered.. Our study, 
like other studies, demonstrates a multi-factorial aetiology of  
AVN in HIV infected patients, but does not give evidence 
of  a causal link between HIV and AVN. It is an important 
finding of  this study to highlight this area of  uncertainty so 
that future studies can define whether the effect is causal or 
simply an association. 
It may be that HIV disease sensitizes an individual to the 
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effect of  alcohol or steroids in causing AVN. Alternatively, 
HIV could be associated with other risks that are known 
to cause AVN such as excessive alcohol consumption 
and steroid use.  On the other hand, several authors have 
described a significantly greater proportion of  HIV positive 
patients with no other known risk factors compared with 
HIV negative patients7,10,13.
In our study, 7/12 patients presented with symptoms of  
AVN at WHO clinical stage III. Data on CD4 counts at 
the time of  AVN diagnosis was available in 7 patients. Six 
of  these patients had a CD4 count of  >200 cells/ul. It is 
difficult to draw any conclusions from this data but some 
studies have suggested that AVN can occur at any level of  
immunosuppression5,7. 
There were no major complications following THR surgery 
in both HIV positive and negative patients. There was also 
no significant difference between the groups, in the pre and 
post-operative Harris hip score checked at six months to one 
year post total hip replacement. This indicated an impressive 
symptomatic improvement. In the South African study on 
hip arthroplasty in HIV-infected patients, all their patients 
were given rifampicin for 9 months as to prevent bacterial 
adherence to implants16. The use of   antibiotics  may have 
been considered to contribute to the lack of  postoperative 
infection in their study patients. Our paper also reports a zero 
early infection rate after arthroplasty , but without resorting 
to long-term prophylactic antibiotics. The findings in our 
study suggest that early response to THR surgery is good 
whether the patient is HIV positive or negative. The absence 
of  early infection and other complications is consistent with 
our studies on outcome after internal fracture fixation in HIV 
positive patients with closed injuries9,24. At present we are 
not aware of  any report of  medium to long- term outcome 
of  arthroplasty in HIV except those with haemophilia25. We 
are unsure whether or not results in haemophiliacs translate 
to other HIV positive patients as discussed previously24,26. 
We have demonstrated that patients with HIV associated 
AVN can get good early results after total hip replacement 
in terms of  pain relief, function and low complication rate, 
but we cannot yet comment on medium to long-term results. 
This study indicates that HIV disease is associated with AVN 
of  the hip , but the aetiology of  AVN may be multifactorial 
even in the presence of  HIV infection. Thus in our unit 
we have now made counseling and HIV testing part of  the 
routine investigation of  all non-traumatic AVN cases. 
There is need for a large study to establish the role of  
hyperlipidaemia  and other risk factors in AVN patients, 
particularly those who are HIV seropositive. 
All orthopaedic surgeons should be aware of  the association 
between HIV and AVN of  the femoral head, and should 
consider counseling and testing for HIV in their routine 
investigation of  the disease.  
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